Challenging Mainstream Narratives

Ted Broer opens by questioning the financial incentives behind statin prescribing, documenting how pharmaceutical and hospital revenue structures create pressure toward medication continuation regardless of individual patient outcome and connecting this to the GLP-1 drug expansion into pediatric prescribing without the long-term safety research both hosts argue any pharmaceutical agent administered to developing patients requires.